tirzepatide shortage fda Compounders protest as removes off list Tirzepatide Shortage Ends - American

| Take home message A recent announcement from Novo Nordisk, the pharmaceutical company that manufactures Wegovy (semaglutide 2.4mg), declared that preliminary results from their latest trial had shown a 20% reduction in the number of major cardiovascular events (MACE), like a heart attack or stroke, compared to placebo

Inflammatory bowel disease (IBD)

A su vez, el ensayo SELECT, con ms de 17.000 participantes, demostr que reduce en un 20% el riesgo de muerte cardiovascular, infarto y accidente cerebrovascular en personas con obesidad y enfermedad cardaca previa

The ongoing research into semaglutides side effects is crucial for improving patient care

if prescribed, it has been done off-label

Some compounded products have a shelf life of 30 days, others up to 90 days